ImmunoCellular Therapeutics Ltd  

(Public, NYSEMKT:IMUC)   Watch this stock  
Find more results for IMUC
1.19
0.00 (0.00%)
Pre-market: 1.18 -0.01 (-0.84%)
Apr 21, 9:23AM EDT  
NYSEMKT real-time data - Disclaimer
Currency in USD
Range     -
52 week 0.65 - 4.00
Open     -
Vol / Avg. 200.00/1.23M
Mkt cap 68.50M
P/E     -
Div/yield     -
EPS -0.17
Shares 57.57M
Beta 3.10
Inst. own 10%
Jun 13, 2014
IMMUNOCELLULAR THERAPEUTICS Annual Shareholder Meeting Add to calendar
May 5, 2014
Q1 2014 IMMUNOCELLULAR THERAPEUTICS Earnings Release (Estimated) Add to calendar
Mar 13, 2014
Q4 2013 IMMUNOCELLULAR THERAPEUTICS Earnings Conference Call
Mar 13, 2014
Q4 2013 IMMUNOCELLULAR THERAPEUTICS Earnings Release
Mar 11, 2014
IMMUNOCELLULAR THERAPEUTICS at ROTH Conference
Feb 10, 2014
IMMUNOCELLULAR THERAPEUTICS at Biotechnology Industry Organization CEO & Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets 1.59% -31.45%
Return on average equity 1.82% -35.53%
Employees 3 -
CDP Score - -

Address

Suite 300, 23622 Calabasas Road
CALABASAS, CA 91302
United States - Map
+1-818-2642300 (Phone)
+1-818-2245287 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors. Immunotherapy is an approach to treat cancer in which a patient�s own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies. The Company�s products include ICT-107, ICT-140, ICT-121, ICT-109 and DIAAD. ICT-107, the pipeline product, is a Phase II therapeutic dendritic cell (DC) vaccine for the treatment of glioblastoma multiforme (GBM), the common and lethal type of brain cancer. ICT-107 is designed to activate a patient�s immune system to target six different tumor-associated antigens. In February 2012, it acquired a world-wide license from the University of Pennsylvania and The John Hopkins University (JHU).

Officers and directors

John S. Yu M.D. Chairman of the Board, Chief Scientific Officer
Age: 49
Bio & Compensation  - Reuters
Andrew Gengos President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Anthony J. Gringeri Ph.D. Senior Vice President - Strategic Resources
Bio & Compensation  - Reuters
David E. Fractor Principal Accounting Officer, Vice President - Finance
Age: 53
Bio & Compensation  - Reuters
Peter Ho Director - Business Development and Licensing
Bio & Compensation  - Reuters
Rahul Singhvi Lead Independent Director
Age: 48
Bio & Compensation  - Reuters
Richard H. Chin M.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
Helen S. Kim Independent Director
Age: 50
Bio & Compensation  - Reuters
Gary S. Titus Independent Director
Age: 53
Bio & Compensation  - Reuters